Article Text

PDF
CP-035 Evaluation of the therapeutic strategies used for the treatment of hepatitis C virus genotype 3 infection
  1. JC Del Río Valencia,
  2. R Asensi Díez,
  3. R Madera Pajin,
  4. I Muñoz Castillo
  1. Hospital Regional Universitario Carlos Haya, Servicio Farmacia, Malaga, Spain

Abstract

Background Hepatitis C is a serious health problem with a high prevalence rate, and is the leading cause of liver transplantation. The development of well tolerated and highly effective direct acting antivirals (DAAs) for hepatitis C virus (HCV) has dramatically changed the therapeutic landscape.

Purpose To assess the effectiveness of sosbuvir/daclatasvir (SOF+DCV) compared with sofosbuvir/ledipasvir (SOF/LDV) used for the treatment of HCV genotype 3 infection.

Material and methods This was a retrospective and observational study between April 2015 and January 2016. Inclusion criteria: patients with HCV genotype 3 infection treated with either SOF/LDV±ribavirin (RBV) or SOF+DCV during the study period. Exclusion criteria: patients with no data available. Outcomes collected: demographics(age and sex); clinical data(baseline viral load (VL), SVR at week 12 (SVR12), defined as HCV RNA titres <15 IU/mL); METAVIR score(F0–F4); liver transplant; HIV co-infection; and previous treatments for HCV. Data were collected from the medical records of patients.

Results Treatment with SOF/LDV±RBV: 20 patients were included (65% men) with a mean age of 53.05±9.05 years. Patients were treated for 12 weeks. METAVIR score: F4 (cirrhosis) (45%), F3 (35%), F2 (15%) and F1 (5%). 10% of patients were HIV coinfected, 15% had a liver transplant and 30% were pretreated with RBV/peginterferon. 45% of patients had an initial VL >800 000UI/mL. Treatment SOF/LDV: naive-non-cirrhotic patients (n=5) achieving SVR12 60%, naive-cirrhotic (n=5) achieving SVR12 only 40%; pretreated non-cirrhotic (n=3) achieving SVR12 66.66% and 1 pretreated cirrhotic who did not achieve SVR12. Treatment SOF/LDV/RBV: naive-non-cirrhotic (n=3) and naïve-cirrhotic (n=1), all achieved SVR12; pretreated cirrhotic (n=2), only one patient achieved SVR12.

Treatment with SOF+DCV: 20 patients (85% men) were included with a mean age of 53.05±9.05 years. Patients were treated for 12 weeks. METAVIR score: F4 (cirrhosis) 50%, F3 (20%), F2 (20%) and F1 (10%). HIV coinfected patients 45%, pretreated with RBV/peginterferon 25% and 30% had basal VL >800 000UI/mL. All patients (19/20=95%) achieved SVR12 except 1 pretreated cirrhotic patient.

Conclusion Treatment with SOF+DCV seemed to be more effective in our study. This matches the upper SVR12 rate achieved in ALLY-3 for SOF+DCV compared with results obtained in ELECTRON-2 for SOF/LDV in genotype 3, although the sample size and different baseline characteristics of the patients could have influenced these results.

No conflict of interest

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.